211 related articles for article (PubMed ID: 22102173)
1. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
Cheng J; Ha M; Wang Y; Sun J; Chen J; Wang Y; Tong C
J Cancer Res Clin Oncol; 2012 Feb; 138(2):231-8. PubMed ID: 22102173
[TBL] [Abstract][Full Text] [Related]
2. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
3. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
4. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Campanini N; Azzoni C; Bordi C; Ardizzoni A;
Br J Cancer; 2013 Apr; 108(8):1695-703. PubMed ID: 23549037
[TBL] [Abstract][Full Text] [Related]
5. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
6. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
8. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
10. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
Li P; Wang YD; Cheng J; Chen JC; Ha MW
Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
Han JY; Lee GK; Lim KY; Lee YJ; Nam BH; Lee JS
Cancer Res Treat; 2017 Jul; 49(3):678-687. PubMed ID: 27737534
[TBL] [Abstract][Full Text] [Related]
13. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
14. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
15. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer.
Li C; Liu M; Yan A; Liu W; Hou J; Cai L; Dong X
Tumour Biol; 2014 Dec; 35(12):12707-12. PubMed ID: 25217323
[TBL] [Abstract][Full Text] [Related]
18. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Zhang L; Liu T; Zhang JQ
Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):212-6. PubMed ID: 21575522
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.
Xu ZC; Cai HZ; Li X; Xu WZ; Xu T; Yu B; Zou Q; Xu L
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
